Status:

COMPLETED

The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study

Lead Sponsor:

Bruyère Health Research Institute.

Conditions:

Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this feasibility study is to inform a larger randomized, placebo-controlled, double blind, parallel-group, single-centre trial of an oral, daily administered single dose of melatonin to...

Detailed Description

Delirium is a very common and distressing neuropsychiatric syndrome in palliative care and a variety of other settings. It is associated with increases in morbidity, mortality, health care costs and m...

Eligibility Criteria

Inclusion

  • Males and females ≥ 18 years
  • Cancer diagnosis
  • Admitted to Palliative Care Unit
  • English speaking
  • Cognitive capacity to give informed consent or substitute decision maker is accessible to provide consent
  • Palliative Performance Scale ≥ 30% at the time of consent

Exclusion

  • Delirium present on admission (assessed clinically with the CAM)
  • Known psychotic disorder other than dementia
  • Inability to take medications sublingually or via gastrostomy tube
  • Known allergy to melatonin or placebo content
  • Use of melatonin within the two weeks preceding admission
  • Patient on warfarin treatment or other oral anticoagulant
  • Communication problems that cannot be accommodated, including deafness, tracheostomy, aphasia, dysarthria or emotional distress
  • On other investigational agents or treatments
  • Pregnancy or lactation
  • Severe visual impairment or designated legally blind
  • Immunosuppressant medication use in the context of autoimmune disease or post organ transplantation

Key Trial Info

Start Date :

December 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2016

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT02200172

Start Date

December 1 2014

End Date

April 1 2016

Last Update

July 19 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Bruyère Continuing Care

Ottawa, Ontario, Canada, K1N 5C8

The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study | DecenTrialz